Differences in Metabolite-Mediated Toxicity of Tamoxifen in Rodents versus Humans Elucidated with DNA/Microsome Electro-Optical Arrays and Nanoreactors
- 23 January 2009
- journal article
- research article
- Published by American Chemical Society (ACS) in Chemical Research in Toxicology
- Vol. 22 (2) , 341-347
Abstract
Tamoxifen, a therapeutic and chemopreventive breast cancer drug, was chosen as a model compound because of acknowledged species specific toxicity differences. Emerging approaches utilizing electro-optical arrays and nanoreactors based on DNA/microsome films were used to compare metabolite-mediated toxicity differences of tamoxifen in rodents versus humans. Hits triggered by liver enzyme metabolism were first provided by arrays utilizing a DNA damage end point. The arrays feature thin-film spots containing an electrochemiluminescent (ECL) ruthenium polymer ([Ru(bpy)2PVP10]2+; PVP, polyvinylpyridine), DNA, and liver microsomes. When DNA damage resulted from reactions with tamoxifen metabolites, it was detected by an increase in light from the oxidation of the damaged DNA by the ECL metallopolymer. The slope of ECL generation versus enzyme reaction time correlated with the rate of DNA damage. An approximate 2-fold greater ECL turnover rate was observed for spots with rat liver microsomes compared to that with human liver microsomes. These results were supported by liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis of reaction products using nanoreactors featuring analogous films on silica nanoparticles, allowing the direct measurement of the relative formation rate for α-(N2-deoxyguanosinyl)tamoxifen. We observed 2−5-fold more rapid formation rates for three major metabolites, i.e., α-hydroxytamoxifen, 4-hydroxytamoxifen, and tamoxifen N-oxide, catalyzed by rat liver microsomes compared to human liver microsomes. Comparable formation rates were observed for N-desmethyl tamoxifen with rat and human liver microsomes. A better detoxifying capacity for human liver microsomes than rat liver microsomes was confirmed utilizing glucuronyltransferase in microsomes together with UDP-glucuronic acid. Taken together, lower genotoxicity and higher detoxication rates presented by human liver microsomes correlate with the lower risk of tamoxifen in causing liver carcinoma in humans, provided the glucuronidation pathway is active.Keywords
This publication has 38 references indexed in Scilit:
- Synergistic Metabolic Toxicity Screening Using Microsome/DNA Electrochemiluminescent Arrays and NanoreactorsAnalytical Chemistry, 2008
- Biochemical applications of ultrathin films of enzymes, polyions and DNAChemical Communications, 2007
- Genotoxicity screening for N-nitroso compounds. Electrochemical and electrochemiluminescent detection of human enzyme-generated DNA damage from N-nitrosopyrrolidineChemical Communications, 2007
- Electrochemiluminescent Arrays for Cytochrome P450-Activated Genotoxicity Screening. DNA Damage from Benzo[a]pyrene MetabolitesAnalytical Chemistry, 2007
- FORMATION OF TAMOXIFEN-DNA ADDUCTS VIA O-SULFONATION, NOT O-ACETYLATION, OF α-HYDROXYTAMOXIFEN IN RAT AND HUMAN LIVERSDrug Metabolism and Disposition, 2005
- Electrospray Ionization-Tandem Mass Spectrometry and 32P-Postlabeling Analyses of Tamoxifen-DNA Adducts in HumansJNCI: Journal of the National Cancer Institute, 2004
- Tamoxifen: a most unlikely pioneering medicineNature Reviews Drug Discovery, 2003
- Quantification of Tamoxifen DNA Adducts Using On-Line Sample Preparation and HPLC-Electrospray Ionization Tandem Mass SpectrometryChemical Research in Toxicology, 2003
- Tamoxifen−DNA Adducts Detected in the Endometrium of Women Treated with TamoxifenChemical Research in Toxicology, 1999
- Lack of evidence from HPLC 32P-post-labelling for tamoxifenDNA adducts in the human endometriumCarcinogenesis, 1999